lifestyle.celebhomes.net
Home
Sample Page
Author:
Longeveron
Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
May 8, 2026
Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026
May 5, 2026
Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
April 8, 2026
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update
March 18, 2026
Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026
March 12, 2026
Longeveron Announces Closing of Private Placement of up to $30 Million
March 11, 2026
Longeveron Announces Private Placement of up to $30 Million
March 10, 2026
Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program
February 6, 2026
Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
January 29, 2026
Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
January 26, 2026